VTYX
Companies
NASDAQ
Ventyx Biosciences Inc.
Health Care
$2.37
+$0.18 (+8.22%)
Price Chart
Overview
About VTYX
we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.
Market Cap
$229.8M
Volume
3.0M
Avg. Volume
2.2M
P/E Ratio
-0.3888837
Dividend Yield
0.00%
Employees
44.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.02
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, VTYX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$229.8M
Volume3.0M
P/E Ratio-0.39
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 28, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025